Last reviewed · How we verify

Trifarotene 0.005 % Topical Cream — Competitive Intelligence Brief

Trifarotene 0.005 % Topical Cream (Trifarotene 0.005 % Topical Cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: retinoid. Area: Dermatology.

phase 3 retinoid RAR-gamma Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Trifarotene 0.005 % Topical Cream (Trifarotene 0.005 % Topical Cream) — Teva Pharmaceuticals USA. Trifarotene is a retinoic acid receptor gamma (RAR-gamma) agonist that modulates the expression of genes involved in cell differentiation and proliferation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Trifarotene 0.005 % Topical Cream TARGET Trifarotene 0.005 % Topical Cream Teva Pharmaceuticals USA phase 3 retinoid RAR-gamma
tretinoin 0.025% cream tretinoin 0.025% cream Wake Forest University marketed Retinoid Retinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma)
Tretinoin gel Tretinoin gel Bausch Health Americas, Inc. marketed Retinoid Retinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma)
Tretinoin cream 0.05 Tretinoin cream 0.05 Massachusetts General Hospital marketed Retinoid Retinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma)
Tazorac Cream, 0.1% Tazorac Cream, 0.1% Dr. Reddy's Laboratories Limited phase 3 Retinoid Retinoic acid receptor (RAR), particularly RAR-beta and RAR-gamma
Sohonos PALOVAROTENE Ipsen marketed Retinoid [EPC] Retinoic acid receptor gamma 2023-01-01
TRIFAROTENE TRIFAROTENE marketed Retinoid [EPC] 2019-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (retinoid class)

  1. Galderma R&D · 2 drugs in this class
  2. Encube Ethicals Pvt. Ltd. · 1 drug in this class
  3. Fougera Pharmaceuticals Inc. · 1 drug in this class
  4. Kowa Company, Ltd. · 1 drug in this class
  5. South Plains Oncology Consortium · 1 drug in this class
  6. Stiefel, a GSK Company · 1 drug in this class
  7. Actavis Inc. · 1 drug in this class
  8. Teva Pharmaceuticals USA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trifarotene 0.005 % Topical Cream — Competitive Intelligence Brief. https://druglandscape.com/ci/trifarotene-0-005-topical-cream. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: